These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 16926619)

  • 21. The children's Yale-Brown obsessive-compulsive scale: psychometric properties of child- and parent-report formats.
    Storch EA; Murphy TK; Adkins JW; Lewin AB; Geffken GR; Johns NB; Jann KE; Goodman WK
    J Anxiety Disord; 2006; 20(8):1055-70. PubMed ID: 16503111
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reliability and validity of the Japanese version of the Yale-Brown Obsessive-Compulsive Scale.
    Nakajima T; Nakamura M; Taga C; Yamagami S; Kiriike N; Nagata T; Saitoh M; Kinoshita T; Okajima Y; Hanada M
    Psychiatry Clin Neurosci; 1995 May; 49(2):121-6. PubMed ID: 8726128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder.
    Hollander E; Wasserman S; Swanson EN; Chaplin W; Schapiro ML; Zagursky K; Novotny S
    J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):541-8. PubMed ID: 17069543
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of risperidone and parent training on adaptive functioning in children with pervasive developmental disorders and serious behavioral problems.
    Scahill L; McDougle CJ; Aman MG; Johnson C; Handen B; Bearss K; Dziura J; Butter E; Swiezy NG; Arnold LE; Stigler KA; Sukhodolsky DD; Lecavalier L; Pozdol SL; Nikolov R; Hollway JA; Korzekwa P; Gavaletz A; Kohn AE; Koenig K; Grinnon S; Mulick JA; Yu S; Vitiello B;
    J Am Acad Child Adolesc Psychiatry; 2012 Feb; 51(2):136-46. PubMed ID: 22265360
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methylphenidate for pervasive developmental disorders: safety and efficacy of acute single dose test and ongoing therapy: an open-pilot study.
    Di Martino A; Melis G; Cianchetti C; Zuddas A
    J Child Adolesc Psychopharmacol; 2004; 14(2):207-18. PubMed ID: 15319018
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity.
    Jahromi LB; Kasari CL; McCracken JT; Lee LS; Aman MG; McDougle CJ; Scahill L; Tierney E; Arnold LE; Vitiello B; Ritz L; Witwer A; Kustan E; Ghuman J; Posey DJ
    J Autism Dev Disord; 2009 Mar; 39(3):395-404. PubMed ID: 18752063
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Developmental disabilities modification of the Children's Global Assessment Scale.
    Wagner A; Lecavalier L; Arnold LE; Aman MG; Scahill L; Stigler KA; Johnson CR; McDougle CJ; Vitiello B
    Biol Psychiatry; 2007 Feb; 61(4):504-11. PubMed ID: 17276748
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Hungarian translation of the Dimensional Yale-Brown Obsessive-Compulsive Scale and our first experiences with the test].
    Harsányi A; Csigó K; Demeter G; Rajnai C; Németh A; Racsmány M
    Psychiatr Hung; 2009; 24(1):18-59. PubMed ID: 19542567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factor analytic study of the Children's Yale-Brown Obsessive-Compulsive Scale.
    Storch EA; Murphy TK; Geffken GR; Bagner DM; Soto O; Sajid M; Allen P; Killiany EM; Goodman WK
    J Clin Child Adolesc Psychol; 2005 Jun; 34(2):312-9. PubMed ID: 15901231
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ.
    Aman MG; Binder C; Turgay A
    J Child Adolesc Psychopharmacol; 2004; 14(2):243-54. PubMed ID: 15319021
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development and psychometric evaluation of the Yale-Brown Obsessive-Compulsive Scale--Second Edition.
    Storch EA; Rasmussen SA; Price LH; Larson MJ; Murphy TK; Goodman WK
    Psychol Assess; 2010 Jun; 22(2):223-32. PubMed ID: 20528050
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reliability and validity of the Pervasive Developmental Disorders Assessment System.
    Kurita H; Koyama T; Inoue K
    Psychiatry Clin Neurosci; 2008 Apr; 62(2):226-33. PubMed ID: 18412847
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical features of obsessive-compulsive disorder with pervasive developmental disorder].
    Yamashita Y
    Seishin Shinkeigaku Zasshi; 2010; 112(9):853-66. PubMed ID: 21077294
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [An experience of the application of rispolept in childhood schizophrenia].
    Kozlova IA; Burelomova IV; Goriunov AV; Grebchenko IuF; Masikhina SN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2001; 101(7):35-8. PubMed ID: 11523392
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Montefiore-Einstein Rigidity Scale-Revised (MERS-R): Development, administration, reliability, and validity in child and adult Autism Spectrum Disorder (ASD).
    Taylor BP; Liu J; Mowrey W; Eule E; Bolognani F; Hollander E
    J Psychiatr Res; 2022 Mar; 147():142-147. PubMed ID: 35032947
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Autistic dimension in obsessive-compulsive disorder in adolescence].
    Ardizzone I; Soletti L; Panunzi S; Carratelli TI
    Riv Psichiatr; 2010; 45(2):94-101. PubMed ID: 20568580
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A severity rating scale for body dysmorphic disorder: development, reliability, and validity of a modified version of the Yale-Brown Obsessive Compulsive Scale.
    Phillips KA; Hollander E; Rasmussen SA; Aronowitz BR; DeCaria C; Goodman WK
    Psychopharmacol Bull; 1997; 33(1):17-22. PubMed ID: 9133747
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pharmacological treatments in patients with pervasive developmental disorders: A review].
    Béhérec L; Quilici G; Rosier A; Gerardin P; Campion D; Guillin O
    Encephale; 2014 Apr; 40(2):188-96. PubMed ID: 24369879
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The PDD Behavior Inventory: a rating scale for assessing response to intervention in children with pervasive developmental disorder.
    Cohen IL; Schmidt-Lackner S; Romanczyk R; Sudhalter V
    J Autism Dev Disord; 2003 Feb; 33(1):31-45. PubMed ID: 12708578
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Yokukansan (TJ-54) for irritability associated with pervasive developmental disorder in children and adolescents: a 12-week prospective, open-label study.
    Wake R; Miyaoka T; Inagaki T; Furuya M; Ieda M; Liaury K; Kishi K; Horiguchi J
    J Child Adolesc Psychopharmacol; 2013 Jun; 23(5):329-36. PubMed ID: 23782127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.